ELV
Elevance Health Inc. NYSE Listed Oct 30, 2001$372.85
Mkt Cap $81.0B
52w Low $273.71
65.9% of range
52w High $424.24
50d MA $314.36
200d MA $326.24
P/E (TTM)
14.8x
EV/EBITDA
10.5x
P/B
1.9x
Debt/Equity
0.8x
ROE
11.9%
P/FCF
24.5x
RSI (14)
—
ATR (14)
—
Beta
0.50
50d MA
$314.36
200d MA
$326.24
Avg Volume
1.9M
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
220 Virginia Avenue · Indianapolis, IN 46204 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | AMC | 11.03 | 12.58 | +14.1% | 328.20 | +0.4% | +5.5% | +5.0% | +8.6% | +10.5% | +14.8% | — |
| Jan 28, 2026 | AMC | 3.10 | 3.33 | +7.4% | 341.85 | +0.0% | +1.5% | +1.1% | -0.0% | -0.9% | -0.4% | — |
| Oct 21, 2025 | AMC | 4.93 | 6.03 | +22.3% | 349.75 | -0.8% | -1.3% | -1.0% | -2.1% | -2.1% | -3.0% | — |
| Jul 17, 2025 | AMC | 8.91 | 8.84 | -0.8% | 302.45 | -4.0% | -8.4% | -8.6% | -6.9% | -1.9% | -7.3% | — |
| Apr 22, 2025 | AMC | 11.41 | 11.97 | +4.9% | 415.90 | -0.3% | +2.6% | +3.1% | +1.4% | -0.5% | -0.5% | — |
| Jan 23, 2025 | AMC | 3.80 | 3.84 | +1.1% | 401.36 | -1.0% | -0.1% | +2.5% | +1.0% | -0.3% | -0.5% | — |
| Oct 17, 2024 | AMC | 9.66 | 8.37 | -13.4% | 444.35 | -1.8% | -3.1% | -5.0% | -5.5% | -6.5% | -5.7% | — |
| Jul 17, 2024 | AMC | 10.01 | 10.12 | +1.1% | 520.93 | -2.6% | -3.1% | -4.0% | -3.3% | -3.6% | -1.7% | — |
| Apr 18, 2024 | AMC | 10.53 | 10.64 | +1.0% | 525.19 | +1.4% | +1.2% | +1.3% | +1.5% | +1.6% | +2.8% | — |
| Jan 24, 2024 | AMC | 5.55 | 5.62 | +1.3% | 473.67 | -0.4% | +1.4% | +2.1% | +2.7% | +3.9% | +4.2% | — |
| Oct 18, 2023 | AMC | 8.45 | 8.99 | +6.4% | 469.31 | -0.2% | -1.3% | -3.3% | -3.7% | -3.6% | -4.1% | — |
| Jul 19, 2023 | AMC | 8.80 | 9.04 | +2.7% | 463.21 | +1.3% | +2.7% | +2.7% | +1.7% | +2.7% | +1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | BofA Securities | Upgrade | Neutral → Buy | $435 | $362.74 | $365.20 | +0.7% | +3.8% | +3.8% | +2.7% | +2.5% | +1.7% |
| Apr 28 | JP Morgan | Maintains | Overweight → Overweight | — | $356.34 | $359.17 | +0.8% | +1.8% | +5.7% | +5.6% | +4.6% | +4.4% |
| Apr 24 | Guggenheim | Maintains | Buy → Buy | — | $346.29 | $348.00 | +0.5% | -0.4% | +2.9% | +4.8% | +8.8% | +8.7% |
| Apr 24 | Barclays | Maintains | Overweight → Overweight | — | $346.29 | $348.00 | +0.5% | -0.4% | +2.9% | +4.8% | +8.8% | +8.7% |
| Apr 23 | Evercore ISI | Maintains | In Line → In Line | — | $328.20 | $329.36 | +0.4% | +5.5% | +5.0% | +8.6% | +10.5% | +14.8% |
| Apr 23 | Baird | Maintains | Neutral → Neutral | — | $328.20 | $329.36 | +0.4% | +5.5% | +5.0% | +8.6% | +10.5% | +14.8% |
| Apr 20 | Jefferies | Maintains | Buy → Buy | — | $323.05 | $321.43 | -0.5% | -1.1% | +1.6% | +1.6% | +7.2% | +6.7% |
| Apr 13 | Truist | Maintains | Buy → Buy | — | $311.53 | $309.51 | -0.6% | +1.5% | +0.6% | -0.1% | +1.4% | +3.7% |
| Mar 11 | Mizuho | Maintains | Outperform → Outperform | — | $282.68 | $280.19 | -0.9% | +2.5% | +1.8% | +3.2% | +3.3% | +4.6% |
| Feb 2 | Truist | Maintains | Buy → Buy | — | $345.74 | $342.29 | -1.0% | -1.1% | -2.1% | -1.5% | -3.9% | -2.0% |
| Feb 2 | JP Morgan | Maintains | Overweight → Overweight | — | $345.74 | $342.29 | -1.0% | -1.1% | -2.1% | -1.5% | -3.9% | -2.0% |
| Jan 30 | Barclays | Maintains | Overweight → Overweight | — | $346.98 | $347.90 | +0.3% | -0.4% | -1.5% | -2.4% | -1.8% | -4.2% |
| Jan 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $346.98 | $347.90 | +0.3% | -0.4% | -1.5% | -2.4% | -1.8% | -4.2% |
| Jan 29 | Guggenheim | Maintains | Buy → Buy | — | $341.85 | $342.00 | +0.0% | +1.5% | +1.1% | -0.0% | -0.9% | -0.4% |
| Jan 22 | Guggenheim | Maintains | Buy → Buy | — | $369.88 | $368.66 | -0.3% | +0.6% | +0.3% | +1.9% | -12.7% | -7.6% |
| Jan 8 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $366.69 | $372.16 | +1.5% | +2.2% | +1.7% | +2.3% | +1.1% | +1.7% |
| Jan 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $371.37 | $373.13 | +0.5% | -1.3% | +0.9% | +0.4% | +1.0% | -0.2% |
| Jan 5 | Barclays | Maintains | Overweight → Overweight | — | $354.25 | $353.09 | -0.3% | +2.6% | +4.8% | +3.5% | +5.8% | +5.2% |
| Dec 19 | Deutsche Bank | Downgrade | Buy → Hold | — | $344.60 | $337.65 | -2.0% | -1.1% | -0.1% | -0.4% | -0.4% | +1.5% |
| Dec 18 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $345.96 | $342.08 | -1.1% | -0.4% | -1.5% | -0.5% | -0.8% | -0.8% |
| Nov 26 | TD Cowen | Maintains | Buy → Buy | — | $336.27 | $336.16 | -0.0% | +0.7% | +0.6% | -2.0% | -1.6% | -1.6% |
| Nov 4 | Mizuho | Maintains | Outperform → Outperform | — | $313.19 | $310.46 | -0.9% | +1.1% | +1.6% | +0.4% | +1.5% | -3.0% |
| Oct 28 | JP Morgan | Maintains | Overweight → Overweight | — | $342.49 | $342.49 | +0.0% | -0.9% | -1.8% | -6.0% | -7.4% | -8.6% |
| Oct 23 | TD Cowen | Maintains | Buy → Buy | — | $345.21 | $338.66 | -1.9% | +0.3% | -0.8% | -0.8% | -1.7% | -2.6% |
| Oct 22 | Wells Fargo | Maintains | Overweight → Overweight | — | $349.75 | $346.98 | -0.8% | -1.3% | -1.0% | -2.1% | -2.1% | -3.0% |
| Oct 22 | Barclays | Maintains | Overweight → Overweight | — | $349.75 | $346.98 | -0.8% | -1.3% | -1.0% | -2.1% | -2.1% | -3.0% |
| Oct 14 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $351.42 | $345.12 | -1.8% | -0.3% | -0.5% | -0.9% | -0.8% | +0.8% |
| Oct 10 | BofA Securities | Maintains | Neutral → Neutral | — | $358.13 | $360.23 | +0.6% | -1.4% | -1.9% | -2.1% | -2.4% | -2.8% |
| Oct 9 | Mizuho | Maintains | Outperform → Outperform | — | $362.34 | $363.90 | +0.4% | -1.2% | -2.5% | -3.0% | -3.3% | -3.5% |
| Oct 9 | Barclays | Maintains | Overweight → Overweight | — | $362.34 | $363.90 | +0.4% | -1.2% | -2.5% | -3.0% | -3.3% | -3.5% |
| Oct 8 | Guggenheim | Maintains | Buy → Buy | — | $357.49 | $358.11 | +0.2% | +1.4% | +0.2% | -1.2% | -1.7% | -2.0% |
| Oct 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $349.94 | $353.91 | +1.1% | +2.2% | +3.5% | +2.3% | +0.9% | +0.4% |
| Sep 5 | UBS | Maintains | Buy → Buy | — | $308.05 | $308.50 | +0.1% | +1.8% | +0.0% | +2.3% | -0.4% | +2.2% |
| Sep 4 | Barclays | Maintains | Overweight → Overweight | — | $321.59 | $308.60 | -4.0% | -4.2% | -2.5% | -4.2% | -2.0% | -4.6% |
| Aug 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $295.43 | $311.00 | +5.3% | +4.8% | +4.7% | +5.6% | +4.9% | +4.8% |
| Jul 25 | Baird | Maintains | Neutral → Neutral | — | $280.43 | $283.66 | +1.2% | +3.1% | +2.0% | +3.0% | +4.7% | +0.9% |
| Jul 22 | Barclays | Maintains | Overweight → Overweight | — | $276.45 | $275.99 | -0.2% | +1.9% | +7.3% | +1.4% | +4.6% | +3.4% |
| Jul 22 | JP Morgan | Maintains | Overweight → Overweight | — | $276.45 | $275.99 | -0.2% | +1.9% | +7.3% | +1.4% | +4.6% | +3.4% |
| Jul 21 | Argus | Downgrade | Buy → Hold | — | $277.09 | $278.35 | +0.5% | -0.2% | +1.7% | +7.0% | +1.2% | +4.3% |
| Jul 18 | Guggenheim | Maintains | Buy → Buy | — | $302.45 | $290.31 | -4.0% | -8.4% | -8.6% | -6.9% | -1.9% | -7.3% |
| Jul 18 | UBS | Maintains | Buy → Buy | — | $302.45 | $290.31 | -4.0% | -8.4% | -8.6% | -6.9% | -1.9% | -7.3% |
| Jul 18 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $302.45 | $290.31 | -4.0% | -8.4% | -8.6% | -6.9% | -1.9% | -7.3% |
| Jul 18 | Barclays | Maintains | Overweight → Overweight | — | $302.45 | $290.31 | -4.0% | -8.4% | -8.6% | -6.9% | -1.9% | -7.3% |
| Jul 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $302.45 | $290.31 | -4.0% | -8.4% | -8.6% | -6.9% | -1.9% | -7.3% |
| Jul 16 | Truist | Maintains | Buy → Buy | — | $336.21 | $337.60 | +0.4% | +2.5% | -10.0% | -17.6% | -17.8% | -16.2% |
| Jul 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $340.07 | $339.43 | -0.2% | -1.1% | +1.3% | -11.1% | -18.5% | -18.7% |
| Jul 14 | UBS | Maintains | Buy → Buy | — | $340.67 | $337.75 | -0.9% | -0.2% | -1.3% | +1.1% | -11.2% | -18.7% |
| Jul 9 | Barclays | Maintains | Overweight → Overweight | — | $349.46 | $347.00 | -0.7% | -0.9% | -1.0% | -2.5% | -2.7% | -3.8% |
| Jun 9 | Truist | Maintains | Buy → Buy | — | $393.36 | $392.65 | -0.2% | -1.0% | -2.4% | -3.2% | -1.8% | -2.2% |
| Jun 4 | RBC Capital | Maintains | Outperform → Outperform | — | $378.96 | $379.53 | +0.2% | +0.3% | +1.5% | +3.8% | +2.8% | +1.3% |
No insider trades available.
8-K · 7.01
! Medium
Axogen, Inc. -- 8-K 7.01: Regulation FD Disclosure
Axogen disclosed a financial results presentation available for investor and analyst discussions, though the filing provides limited detail on specific business updates or financial performance metrics.
Apr 28
8-K
Elevance Health, Inc. -- 8-K Filing
Elevance Health issued forward-looking statements regarding financial projections, operational plans, and future performance, signaling management's expectations but acknowledging inherent uncertainties in predicting outcomes.
Apr 22
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An executive's equity compensation structure with performance conditions and service requirements suggests the company is retaining leadership talent while tying rewards to sustained performance, which could indicate confidence in strategic direction but also potential execution risks if targets aren't met.
Apr 2
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
CVS appointed Gallina, an independent director and audit committee financial expert, strengthening board oversight and governance credibility, which typically reassures investors about financial integrity and risk management.
Mar 19
8-K
Unknown — 8-K Filing
ELV's forward-looking guidance for 2026 earnings signals management confidence in sustained growth, making the stock attractive to investors seeking visibility into near-term profitability expansion.
Mar 10
8-K
Elevance Health, Inc. -- 8-K Filing
Elevance Health issued forward-looking statements regarding financial projections, operational plans, and future performance, which carry risks and may not materialize as anticipated.
Mar 2
8-K · 5.02
!!! Very High
Elevance Health, Inc. -- 8-K 5.02: Executive Change
Elevance Health's executive vice president of Carelon is departing May 2026 but staying as advisor through year-end to ensure operational continuity during leadership transition.
Feb 26
Data updated apr 25, 2026 6:59am
· Source: massive.com